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Abstract
Objectives—The purpose of this review was to evaluate whether the Penn Resiliency Program 
(PRP), a group cognitive-behavioral intervention, is effective in targeting depressive symptoms in 
youth.
Data sources—We identified 17 controlled evaluations of PRP (N = 2498) measuring 
depressive symptoms via an online search of PsycInfo, Medline, ERIC, and ProQuest 
Dissertations and Theses, and by requesting data from PRP researchers.
Review methods—We combined effect sizes (ESs; Glass’s d), using random effects models at 
post-intervention and two follow-up assessments.
Results—PRP participants reported fewer depressive symptoms at post-intervention and both 
follow-up assessments compared to youth receiving no intervention, with ESs ranging from 0.11 
to 0.21. Limited data show no evidence that PRP is superior to active control conditions. Subgroup 
analyses showed that PRP’s effects were significant at 1 or more follow-up assessments among 
studies using both targeted and universal approaches, when group leaders were research team 
members and community providers, among participants with both low and elevated baseline 
symptoms, and among boys and girls. Preliminary analyses suggest that PRP’s effects on 
depressive disorders may be smaller than those reported in a larger meta-analysis of depression 
prevention programs for older adolescents and adults.
Conclusion—We found evidence that PRP significantly reduces depressive symptoms through 
at least 1 year post-intervention. Future PRP research should examine whether PRP’s effects on 
depressive symptoms lead to clinically meaningful benefits for its participants, whether the 
program is cost-effective, whether CBT skills mediate program effects, and whether PRP is 
effective when delivered under real-world conditions.
Steven M. Brunwasser, Department of Psychology, University of Michigan; Jane E. Gillham, Department of Psychology Swarthmore 
College and Department of Psychology, University of Pennsylvania; Eric Kim, University of Michigan.
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Introduction
Depression is one of the leading causes of disability worldwide (Murray & Lopez, 1997). 
Adolescence is a key time in the etiology of depression with rates increasing dramatically 
from the early to late teen years (Hankin, 2006). As many as 20–24% of youth have major 
depressive episodes by age 18 (Lewinsohn, Rhode, & Seeley, 1998). Elevated but sub-
clinical levels of depressive symptoms are also common in adolescence (Roberts, 
Lewinsohn, & Seeley, 1991) and are associated with considerable impairment as well as 
increased risk for clinical depression (Gotlib, Lewinsohn, & Seeley, 1995). Widespread 
prevention efforts targeting adolescents may be our best hope at alleviating depression’s 
enormous burden on society.
Researchers and mental health professionals have responded to this need by developing and 
testing prevention programs (see Sutton, 2007 for a recent review). These programs target a 
wide-range of risk factors, such as pessimistic cognitive styles, interpersonal difficulties, and 
family conflict. Most depression prevention programs are adapted from established 
psychotherapies for depression, such as cognitive-behavioral therapy (CBT) and 
interpersonal therapy (IPT).
In recent years, several research teams have published meta-analytic reviews of depression 
prevention programs (Cuijpers, van Straten, Smit, Mihalopoulos, & Beekman, 2008; 
Horowitz & Garber, 2006; Jané-Llopis, Hosman, Jenkins, & Anderson, 2003; Merry, 
McDowell, Hetrick, Bir, & Muller, 2004; Stice, Shaw, Bohon, Marti, & Rohde, 2009). 
These reviews have advanced prevention efforts considerably by allowing researchers to 
take stock of the existing literature and by raising important questions and recommendations 
for future prevention efforts. These meta-analyses indicate that youth who participate in 
depression prevention programs report lower levels of depressive symptoms than those who 
receive no intervention (Horowitz & Garber, 2006; Merry et al., 2004; Stice et al., 2009). In 
addition, participants in depression prevention programs are less likely to develop 
depressive disorders (Cuijpers et al., 2008).
The Penn Resiliency Program (PRP; Gillham, Reivich, & Jaycox, 2008) is one of the most 
widely researched depression prevention programs. PRP is a cognitive-behavioral group 
intervention designed for youth in late childhood and early adolescence (ages 10–14). 
Although typically a school-based program, researchers have evaluated PRP in other 
settings, including primary care clinics and juvenile detention centers. For a description of 
the intervention content see Gillham, Brunwasser, and Freres (2008). Findings from the 
initial efficacy study were promising as PRP prevented depressive symptoms through two 
years of follow-up and reduced the risk for clinically relevant symptoms (Gillham, Reivich, 
Jaycox, & Seligman, 1995). Since that initial study, however, PRP research findings have 
been inconsistent. The majority of studies evaluating PRP have found beneficial effects on 
depressive symptoms in either the overall sample or subgroups of participants. But at least 
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four studies found no significant effects (Gillham, et al., 2008). These conflicting results 
make it difficult to give an overall appraisal of the program’s effectiveness. Few studies 
have evaluated PRP’s effects on depressive disorders.
A priority for future PRP research is to determine whether PRP is likely to benefit youth if 
delivered on a wide scale, as intended. Large scale dissemination would require a 
considerable investment of time, effort, and finances. Such an investment is only justified if 
the existing data show promise. A meta-analytic review can help make this determination. 
We know of 17 controlled studies evaluating PRP’s effects on depressive symptoms with 
more than 2000 participants in total. If a quantitative review of these studies detected no 
effect on depressive symptoms then it would be imprudent to continue evaluating the 
program in its current form or to disseminate the program broadly.
A second priority for PRP research is to understand the program’s inconsistent effects. 
Research that identifies the contexts and subgroups in which PRP is most effective could 
guide future program development and implementation efforts. A meta-analysis can help to 
identify factors that moderate intervention effects. Detecting moderation, however, requires 
considerable statistical power as the analyst compares the strength of effects across 
subgroups of participants (Hedges & Pigott, 2004). Nearly half of the studies evaluating 
PRP have small samples (N < 100) limiting the power of meta-analytic analyses to detect 
moderators. Although it is unlikely that analyses comparing effects across subgroups would 
yield conclusive results at this time, there may be sufficient power to determine whether 
PRP’s effects are significant within subgroups of interest.
It is plausible that PRP’s inconsistencies are attributable to within- and between-study 
differences in participant characteristics. Prevention researchers who employ a targeted 
approach attempt to identify and recruit youth who are at increased risk for depression and, 
as such, in the greatest need of early intervention. Targeted intervention includes selective 
studies, in which participants have a known risk factor for the development of a disorder 
(e.g., parental depression), and indicated studies, in which participants evidence early 
symptoms of the disorder (e.g., sub-clinical depressive symptoms). In contrast, universal 
studies recruit all members of a specific population regardless of their level of risk. 
Depression prevention programs targeting at-risk youth have garnered more support than 
those delivered universally (Horowitz & Garber, 2006; Merry et al., 2004; Stice et al., 
2009). PRP is one of the few depression prevention programs evaluated using both targeted 
and universal approaches. In this review, we examine the magnitude of PRP’s effects in both 
targeted and universal studies.
Most studies of PRP have not found or examined potential moderators of intervention 
effects such as participants’ sex or symptom level. A few studies have found that PRP’s 
effects on depressive symptoms differ in boys and girls. At least one study (Gillham, 
Hamilton, Freres, Patton, & Gallop, 2006) found stronger effects for girls than boys, while 
other studies have found the opposite effect (e.g., Reivich, 1996). Some PRP studies have 
found that participants’ pre-intervention levels of depressive symptoms moderated the 
intervention effects. For example, Gillham and colleagues found that PRP reduced the 
likelihood of receiving a diagnosis of depression or anxiety in participants with elevated but 
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not low baseline symptoms (Gillham, Hamilton, et al., 2006). In this review, we evaluate the 
magnitude of PRP’s effects separately for boys and girls and for participants with elevated 
and low baseline symptoms.
A second possible source of inconsistency in PRP findings is within- and between-study 
differences in intervention provider characteristics. In some PRP studies, members of the 
research team (typically psychologists with extensive training in the cognitive-behavioral 
model, psychology graduate students, or advanced research assistants closely supervised by 
the program developers) led the intervention groups. In other studies, community providers, 
who would likely lead intervention groups if PRP were to be widely disseminated, led the 
intervention groups. Unlike research team members, community providers (e.g., school 
personnel or community mental health providers) typically do not have a direct interest in 
the research outcome. Gillham and colleagues expressed concern that PRP’s inconsistent 
findings could be due partly to an attenuation of intervention effects when studies evaluate 
PRP under real-world conditions (i.e., effectiveness trials) as opposed to optimal research 
conditions (i.e., efficacy trials) (Gillham et al., 2008). A drop-off in intervention effects 
under real-world conditions would hamper dissemination efforts and limit PRP’s utility. In 
this review, we evaluate PRP’s effects among studies with both research team leaders and 
community providers.
The primary purpose of this meta-analysis was to aggregate data across all controlled studies 
to determine whether PRP participants have lower levels of depressive symptoms compared 
to youth who receive no intervention. Additionally, we conducted subgroup analyses to 
evaluate PRP’s effects in different contexts. We expected to find more evidence for PRP’s 
effects among targeted than universal studies. We expected to find more evidence for PRP’s 
effects when research team members rather than community providers led intervention 
groups. We expected PRP’s effects to be significant among both boys and girls and among 
participants with both low and elevated baseline symptoms. Because we lacked power to 
detect moderation, we did not focus on analyses comparing the strength of PRP’s effects 
across subgroups. Although limited data were available, we ran preliminary analyses of 
PRP’s effect on depressive disorders to determine whether the magnitude of PRP’s effects is 
comparable to those reported in larger meta-analyses.
Method
Searching
We identified studies for this review using several methods. First, we conducted a search of 
several online databases: PsycInfo (1990–2009), Medline (1990–2009), ProQuest 
Dissertations & Theses (1990–2009), and ERIC (1990–2009). Search terms included all 
known names that have been used to describe PRP (Penn Resiliency Program, Penn 
Prevention Program, Penn Optimism Program, Penn Program, and Depression Prevention 
Program) and the names of the lead investigators of the PRP research team (Gillham, 
Reivich, Jaycox, Shatté, Cardemil, and Seligman). We limited searches to retrieve only 
articles describing empirical studies published no earlier than 1990, the year PRP was 
developed. The final online search date was February 28, 2009. Second, we cross-referenced 
the citation lists in each of the articles retrieved via the online search and reviewed the 
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citation lists of existing meta-analyses to ensure we uncovered all PRP studies included in 
these reviews. Finally, we consulted a database maintained by the program developers since 
February 2003 that records all research-related requests for the PRP program materials. We 
contacted all researchers who had requested the PRP program materials and asked them to 
provide data from their studies and to complete a survey asking for details about the study 
design, participants, group leaders, and intervention delivery.
Selection
Studies included in the review (1) compared PRP to a control condition, (2) evaluated PRP’s 
effect on depressive symptoms, and (3) reported data both before the intervention began 
(baseline) and at one or more post-intervention assessments. No studies were excluded due 
to sub-optimal research methods (e.g., non-random assignment), however, we report 
intervention effects both including and excluding non-randomized studies. The review 
includes data from both published and unpublished studies.
The first author reviewed the abstracts of all articles retrieved via the online database search 
and obtained the full-text for each article that mentioned PRP by name or described a 
cognitive-behavioral intervention for youth. Both the first and second authors reviewed the 
study descriptions provided by the researchers who responded to our request for data to 
determine if their studies met inclusion criteria. The final determination of which studies 
were to be included in the review was made by the consensus of the first and third authors.
Data Abstraction
The first author coded all study data into an MS Access database and wrote algorithms to 
calculate ESs. A trained undergraduate research assistant (the third author) served as an 
independent coder and reentered all data. When data needed to compute ESs were not 
available in study manuscripts, we contacted the manuscript author(s). In all cases, the 
authors provided the necessary data to calculate effects on depressive symptoms. We also 
coded three dichotomous dummy variables representing between-study subgroups of 
interest: Condition Assignment (random vs. non-random), Participant Risk Status (universal 
vs. targeted), and Group Leader Type (research team members vs. community providers).
We were also interested in evaluating PRP’s effects across two within-study factors: Sex 
(girls vs. boys) and Symptom Level (participants with low vs. elevated baseline symptoms). 
Few PRP studies have reported summary statistics for these subgroups. However, we had 
access to full data sets for nine studies included in this review, allowing us to calculate ESs 
by Sex and Symptom Level. A total of 10 studies provided sufficient data to calculate 
separate ESs for boys and girls and 9 studies provided sufficient data to calculate separate 
ESs for participants with low and elevated baseline symptoms. We classified participants as 
having either low or elevated baseline symptoms based on a CDI cutoff score of 13, a 
recommended cutoff score (Kovacs, 2001). One study (Roberts, Kane, Thomson, Bishop, & 
Hart, 2003) reported separate data for participants with low and elevated baseline symptoms 
based on a CDI cutoff of 15. We chose to include data from this study in the subgroup 
analyses because the cutoff score was close to the one selected for the other studies.
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We then exported the data into the Comprehensive Meta-Analysis Version 2.2.046 software 
(CMA; Biostat, Englewood New Jersey) to conduct analyses. In addition to coding ES data 
and moderators, the first and third authors coded information related to the research design, 
participant demographics, and intervention delivery for each study. We conducted no formal 
evaluation of study design quality but provide detailed information about each study in 
online supplemental tables.
Effects on Depressive Symptoms
Power Analysis—In order to gauge our ability to detect effects on depressive symptoms, 
we conducted power analyses following the procedures described by Hedges & Pigott 
(2001). We calculated our power to detect an effect size of 0.20 (α = .05), an effect that is of 
a magnitude similar to those reported by recent meta-analytic reviews of youth depression 
prevention programs (see Supplemental Table 5).
Calculating Effect Sizes—We calculated ES estimates (i.e., standardized mean 
difference scores) for depressive symptoms by dividing the difference in the control group 
and PRP group means by the control group’s standard deviation (Glass’s d; Glass, McGaw, 
& Smith, 1981): d = (X̄control − X̄PRP)/SDControl. Positive d values indicate fewer depressive 
symptoms in PRP groups compared to control groups. Standardized mean difference scores 
based on small samples tend to be upwardly biased (Hedges, 1981). We applied Hedges’s 
(1981) correction to all d estimates to create an unbiased ES estimate: dU = d ×[1 − (3/4df 
−1)]. Hedges’s correction reduces overestimation of the ES in small studies but has a 
negligible effect on ES estimates in large studies. When the standard deviation in the 
denominator of the ES is based on 50 degrees of freedom or more, d and dU are nearly 
identical (Hedges, 1981).
Studies evaluating PRP have differed in their length of follow-up. We limited analyses to the 
three most commonly reported assessments (post-intervention, 6- to 8-month follow-up, and 
12-month follow-up) and calculated separate ESs for each. When studies measured the same 
outcome variable with more than one instrument, we computed an average ES estimate 
across the different instruments so that no study provided multiple ESs at a given 
assessment. When studies had more than one PRP condition (e.g., an adolescent-only PRP 
group and an adolescent + parent PRP group), we pooled the means and standard deviations 
of the different PRP conditions in order to calculate one ES. When studies compared PRP to 
both a no-intervention control condition and an active control condition, we calculated 
separate ESs comparing PRP to both control conditions.
Assessing Heterogeneity—We used Q tests at all assessments to determine whether 
there were any significant violations of homogeneity in the ES distributions. We also 
evaluated the proportion of heterogeneity between studies using the I2 statistic because 
homogeneity tests tend to be underpowered (Higgins, Thompson, Deeks, & Altman, 2003).
Combining Effect Sizes—We used random effects models when combining ESs across 
studies. Fixed effects models assume that between-study differences are due to sampling 
error alone (Cooper & Hedges, 1994). In contrast, random effects models assume that, in 
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addition to sampling error, there are other sources of between-study variability. Random 
effects models add a separate variance term (νθ) to account for non-sampling error. This 
results in larger ES confidence intervals (Lipsey & Wilson, 2001). The assumptions of 
random effects models seemed more appropriate for this review given that there are 
considerable methodological differences across PRP studies. We followed procedures 
recommended by Lipsey & Wilson (2001) when calculating mean ESs. The unbiased 
standardized mean difference score (dU) for each study was weighted by its inverse variance 
(ω): ω = 1/(SE2 + νθ). The weighted ESs were then added and divided by the sum of the 
inverse variance weights across all studies. This produced a mean ES (d+) for each 
assessment.
Converting Effect Sizes—Although standardized mean difference scores are statistically 
intuitive, they do not lend themselves readily to clinical interpretation (Acion, Peterson, 
Temple, & Arndt, 2006). To facilitate comprehension of ESs, we converted standardized 
mean difference scores into more easily interpretable metrics. First we converted the mean 
ESs on the CDI from standard deviation units to the CDI’s scoring metric. We did this by 
multiplying the mean ES for all studies that used the CDI (k = 16) by the pooled CDI 
standard deviation across the control groups. This product represents the average benefit of 
PRP in the CDI metric (Lipsey & Wilson, 2001). A product of 0.50, for example, means that 
PRP groups scored, on average, half a point lower than the control groups on the CDI.
Second, we converted ESs into estimates of the probability of superiority (PS). The PS score 
is an estimate of the probability that a randomly selected PRP participant had a favorable 
outcome (i.e., lower depressive symptoms) compared to a randomly selected control 
participant. A PS score of 0.50 indicates that there is 50% chance that a randomly selected 
PRP participant has a better score than a randomly selected control participant (i.e., no 
intervention effect). Scores ranging from 0.51 to 1.00 indicate preferable outcome for PRP 
participants whereas scores from 0.00 to 0.49 indicate a preferable outcome for control 
participants (Grissom, 2005). When full data sets were accessible, we calculated PS by 
dividing the Mann-Whitney U statistic by the product of the sample sizes for the PRP and 
control conditions: PS = U/mn. We used an approximate conversion method when there 
were insufficient data to calculate a U statistic: , where Φ is the normal 
cumulative distribution function. The non-parametric Mann-Whitney U method is preferable 
because it does not assume that both groups (in this instance, PRP and control) have normal 
distributions (Acion, et al., 2006); an assumption that is untenable when evaluating 
depressive symptoms in non-clinical samples.
One can easily convert PS scores into a number needed to treat (NNT) score: NNT = 1/[(2 × 
PS) − 1]. NNT, in this circumstance, represents the approximate number of youth who need 
to receive PRP, rather than the control condition, to yield one superior outcome. A superior 
outcome is when a randomly selected PRP participant has a better depressive symptom score 
than a randomly selected control participant (Kraemer & Kupfer, 2005). We provide PS and 
NNT scores for each study in Supplemental Table 7.
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Sensitivity analyses—We conducted several forms of sensitivity analysis to determine 
whether effects on depressive symptoms were robust. We evaluated the influence of each 
individual study on the mean ESs with the one-study-removed procedure in CMA. This is an 
iterative procedure in which mean ESs and confidence intervals are repeatedly recalculated 
excluding one study at a time from the analysis. This procedure allows one to determine 
whether any individual study was influential enough to alter the decision about whether to 
reject the null hypothesis (i.e., d+ = 0).
Studies with null findings are less likely to be published and thus, more likely to go 
undiscovered by reviewers. The “file-drawer problem” causes systematic bias often leading 
to an overestimation of effects in meta-analysis (Rosenthal, 1979). We assessed for the 
existence and impact of publication bias using two procedures. First, we examined funnel 
plots and normal-quantile plots of study ESs at each assessment. These plots allow the 
analyst to detect gaps in the ES distribution that could be indicative of publication bias. If 
publication bias were not a concern, one would expect the distribution of study ESs to be 
normal (Light, Singer, & Willett, 1994; Wang & Bushman, 1998). We then recalculated 
mean ESs adjusting for the possible effect of undiscovered studies using trim-and-fill 
analyses. Trim-and-fill makes the distribution of ESs on a funnel plot normal by eliminating 
outlying ESs and imputing ES estimates for hypothetically missing studies. The mean ES is 
then recalculated with the imputed studies. If the mean ES remains significant, one can have 
increased confidence that missing studies would not have altered the decision about whether 
to reject the null hypothesis (Duval & Tweedie, 2000).
Our inclusion of non-randomized studies could be another source of bias. Random 
assignment to study conditions ensures that baseline between-group differences are due to 
chance. Non-randomization could add systematic error to ES estimates as differences at the 
post-intervention data points could reflect baseline differences rather than intervention 
effects. To ensure that study effects were not driven by non-randomized studies, we reran all 
primary outcome analyses excluding non-randomized studies.
Subgroup & Moderator Analyses—We used Q tests to evaluate whether our subgroup 
variables (Participant Risk Status, Group Leader Type, Symptom Level, and Sex) accounted 
for systematic variance in PRP’s effects. Q tests are akin to ANOVA in that they compare 
within- and between-group variance (using a χ2 test statistic) to determine whether 
variability between groups exceeds chance expectation (Lipsey & Wilson, 2001). When 
evaluating moderators, we used mixed effects modeling which assumes that there are both 
systematic and non-systematic sources of heterogeneity in ES estimates (Lipsey & Wilson, 
2001). Mixed effects models use random effects modeling when aggregating ESs within 
subgroups and fixed effects modeling when aggregating across subgroups (Overton, 1998).
Effects on Depressive Disorders
As noted, few studies have evaluated PRP’s effects on diagnostic outcomes limiting 
statistical power to detect effects on depressive disorders. However, we chose to run 
preliminary analyses with the available diagnostic data in an effort to determine whether the 
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effects in the existing PRP studies are comparable to those reported in a recent, larger meta-
analysis of depression prevention programs (Cuijpers et al., 2008).
Following the example of Cuijpers and colleagues, we evaluated PRP’s effects on 
depressive disorders using both relative risk and relative incidence analyses (Cuijpers et al., 
2008). Relative risk analyses compare the proportion of participants in each condition who 
experience the outcome of interest (i.e., depressive disorders) over the follow-up. For each 
study providing diagnostic data, we calculated risk ratios (RRs) by dividing the PRP group 
risk (i.e., the percentage of PRP participants who received a depression diagnosis) by the 
control group risk. Risk ratios smaller than 1.00 indicate a beneficial effect of PRP whereas 
scores greater than 1.00 indicate a benefit for the control condition. We also calculated the 
number needed to treat (NNT) which represents the number of participants that would need 
to receive the intervention in order to prevent one case of depression. The NNT is calculated 
by taking the inverse of the difference in risk between the control and PRP conditions: NNT 
= 1/(RiskControl−RiskPRP) (Woodward, 2005).
The relative risk approach assumes that all participants completed an equal number of 
diagnostic assessments covering an equal amount of time. This was an unsound assumption 
in this review because individual studies differed in their length of follow-up and many 
participants had incomplete data. We computed a person-years (PY) score for each 
participant in order to account for the discrepancy in the number of diagnostic assessments 
completed. PY scores reflect the total number of years during the follow-up that the person 
went without receiving a depression diagnosis. For example, if a participant completed three 
assessments each covering a 6-month span without receiving a diagnosis, that person 
contributed 1.5 PYs to the analysis. Once a participant met criteria for a depressive disorder, 
he/she stopped contributing PYs. We then calculated the incidence of depression in both the 
PRP and control groups by dividing the total number of participants receiving a depression 
diagnosis at some point during the follow-up by the total number of PYs across participants. 
We then calculated the incidence rate ratio (IRR) by dividing the PRP group’s incidence rate 
by the control group’s incidence rate. IRRs less than 1.00 reflect a benefit of PRP.
We computed both a mean IRR (IRR+) as well as a mean RR (RR+) using random effects 
models. Additionally, we evaluated whether PRP’s effect on depressive disorders among 
two subgroup variables: Sex (boys and girls) and Symptom Level (low vs. elevated baseline 
depressive symptoms based on a CDI cutoff score of 13).
Results
Study Flow
Our online database search yielded 519 manuscripts, 44 of which either identified PRP by 
name or described a cognitive-behavioral prevention program for youth in the abstract. We 
excluded 16 of these studies, after reviewing the full-text of the articles, because they did not 
describe evaluations of PRP. An additional six articles describing PRP were eliminated 
because they either did not report depression data (k = 2) or did not have a control condition 
(k = 4). The remaining 22 manuscripts reported data from 15 separate evaluations of PRP 
that met our inclusion criteria (see Supplemental Table 1). We contacted 19 researchers who 
Brunwasser et al. Page 9
J Consult Clin Psychol. Author manuscript; available in PMC 2015 December 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
requested the PRP manuals for research purposes and received responses from 15. Most of 
these researchers (n = 9) indicated that they had not yet conducted evaluations of PRP. Of 
the six studies evaluating PRP, we excluded four because they either did not assess 
depressive symptoms (k = 2) or did not have a control condition (k = 2). The remaining two 
studies met our inclusion criteria. Thus, a total of 17 evaluations of PRP were included in 
this review (see Figure 1).
Study Characteristics
A total of 2498 youth participated in the 17 PRP studies included in the review. Participants 
ranged in age from 8 to 18 years old. Most studies included in this review used some form of 
random condition assignment (k = 14; n = 2281), either randomizing at the participant, 
classroom, or school level. Three studies provided data only at baseline and immediate post-
intervention assessments, while others evaluated intervention effects as late as three years 
post-intervention. Most studies included in the review used a targeted (k = 11; n = 1408) 
rather than a universal (k = 6; n = 1090) intervention approach. An equal number of studies 
had research team members (k = 8; n = 521) and community providers (k = 8; n = 1884) 
leading intervention groups but the studies with community providers tended to be much 
larger. Community providers included school staff (i.e., teachers and counselors), learning 
mentors, and child mental health professionals working for a managed care organization. In 
a few studies, school staff led the vast majority of intervention groups with research team 
members leading a small number of groups; these studies were coded as having community 
providers as group leaders. One study (Reivich, 1996) had an equal number of researchers 
and school staff leading intervention groups and was excluded from subgroup analyses of 
researchers and community providers.
Four studies compared PRP to both a no-intervention control condition and an active control 
condition. Two of these studies (Gillham, Reivich, Freres, et al., 2007; Reivich, 1996) 
compared PRP to the Penn Enhancement Program (PEP), an alternative intervention 
designed specifically to mimic the “non-cognitive modes of action” (such as adult attention, 
group cohesion, and the discussion of day-to-day problems and feelings) that likely 
contribute to PRP’s effects (Reivich, 1996, p. 23). PEP includes psychoeducation and non-
cognitive skill building exercises (e.g., techniques for goal setting, communication, and 
resisting peer pressure) designed to be relevant to youth with depressive symptoms (Reivich, 
1996; Shatté, 1996). Two studies (Pattison & Lynd-Stevenson, 2001; Wass, 2008) compared 
PRP to conditions designed to control for social contact and group cohesion (see 
Supplemental Table 10).
All but one of the 17 studies included in this review measured depressive symptoms with the 
Children’s Depression Inventory (CDI; Kovacs, 2001). Two studies measured depressive 
symptoms with both the CDI and the Reynolds Adolescent Depression Scale (Reynolds, 
1986). One study measured depressive symptoms with the Depression Self-Rating Scale 
(Birleson, 1981). Only three studies evaluated PRP’s effects on depressive disorders. Two of 
these studies assessed for depressive disorders using standardized diagnostic interviews: the 
Children’s Depression Rating Scale—Revised (Poznanski & Mokros, 1996) and the 
Diagnostic Interview Schedule for Children, Version IV (Shaffer, Fisher, Lucas, Dulcan, & 
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Schwab-Stone, 2000). Participants completed these interviews at regular intervals during the 
studies. The third study evaluated PRP’s effects on depressive disorders using HMO 
computerized medical records (Gillham, Hamilton, et al., 2006).
Coder Agreement
The coders achieved a high level of reliability for the continuous ES data (αs > .90) and 
achieved perfect agreement in coding both Condition Assignment and Participant Risk 
Status (κs = 1.00). The raters had a reliability rating of κ = .79 when coding Group Leader 
Type (15 agreements and 2 discrepancies). The first and second authors resolved all coding 
discrepancies.
Power Analyses
We had a considerable amount of statistical power (0.88 to 0.98) to detect an effect of 0.20 
in our analyses with the overall sample. The power of subgroup analyses was greater than 
0.50 except among the subgroup of participants with elevated symptoms and among the 
subgroup of studies with research team group leaders (see Supplementary Table 5).
Heterogeneity Assessment
There was no evidence that the amount of variability between study ESs exceeded chance 
expectation at any assessment, χ2post(16) = 21.14, p = .17, χ26–8-month(12) = 12.54, p = .40, 
and χ212-month(9) = 6.20, p = .72. The proportion of heterogeneity between studies was less 
than 25% (which is considered low) at all assessments, I2post = 24.30, I26–8-month = 4.28, and 
I212-month = 0.00 (Higgins et al., 2003). See Supplemental Table 6 for details on 
heterogeneity analyses.
Effects on Depressive Symptoms
The mean ES comparing PRP and no-intervention control conditions at post-intervention 
was significant (i.e., significantly different than zero), d+ = 0.11 (95% CI = 0.01, 0.20). PRP 
groups had fewer depressive symptoms than control groups in 14 of 17 studies with ESs 
ranging from −0.61 to 0.59. On average, PRP groups scored 0.86 points lower on the CDI 
(indicating fewer depressive symptoms) than control groups, and PS score ranged from 0.33 
to 0.66. The mean ES was also significant at the 6- to 8-month follow-up, d+ = 0.21 (95% CI 
= 0.11, 0.31). ESs ranged from −0.06 to 0.69, and PRP groups had fewer depressive 
symptoms than control groups in 12 of 13 studies. The average benefit of PRP was 1.75 
points on the CDI at the 6- to 8-month follow-up, and PS scores ranged from 0.48 to 0.69. 
The mean ES remained significant at 12-month follow-up, d+ = 0.20 (95% CI = 0.09, 0.32). 
ESs ranged from −0.10 to 0.61, and PRP groups had fewer depressive symptoms than 
control groups in 9 of 10 studies. PRP groups scored, on average, 1.56 points lower on the 
CDI than control groups at 12-month follow-up, and PS scores ranged from 0.47 to 0.67. 
See Table 1 for a summary of ESs at each assessment.
The mean ES comparing PRP to active control conditions was not significant at either post-
intervention or 6- to 8-month follow-up, d+post = −0.02 (95% CI = −0.19, 0.14) and 
d+6–8month = 0.00 (95% CI = −0.18, 0.19). PRP groups had lower mean depressive symptom 
scores than the active control conditions in only one of four studies at post-intervention and 
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in only one of three studies at 6-to 8-month follow-up (see Supplemental Table 10). Only 
one study compared PRP to an active control condition at the 12-month follow-up 
precluding meta-analytic analyses. The active control conditions had lower mean levels of 
symptoms than no-intervention control conditions in all four studies reporting data at post-
intervention, d+ = 0.10 (95% CI = −0.07, 0.26), and in all three studies reporting data at the 
6- to 8-month assessment, d+ = 0.14 (95% CI = −0.05, 0.33). These effects were not 
significant but were based on limited data (Npost = 568 and N6–8-Month = 428).
Sensitivity analyses—Because the mean ESs comparing PRP and active conditions were 
not significant, we limited sensitivity analyses to effects of PRP compared to no-intervention 
control conditions. Findings from the sensitivity analyses differed considerably between 
post-intervention and the two long-term follow-ups. At post intervention, the one-study-
removed procedure showed that 6 of 17 studies carried enough weight that their removal 
from the analysis would have made the mean ES non-significant. Additionally, the post-
intervention mean ES became non-significant when adjusting for publication bias using the 
trim-and-fill procedure, d+ = 0.09 (95% CI = −0.01, 0.19), and when removing studies using 
a non-randomized design, d+ = 0.09 (95% CI = −0.02, 0.19). Therefore, the post-
intervention effect, while significant, is precarious and warrants cautious interpretation. In 
contrast, there was considerable evidence that the long-term follow-up effects were robust. 
No single study when removed from analyses carried enough weight to nullify the mean ES 
at either follow-up assessment. Additionally the mean ESs remained significant after 
adjusting for possible publication bias with the trim-and-fill procedure, d+6–8-month = 0.17 
(95% CI = 0.07, 0.28) and d+12-month = 0.17 (95% CI = 0.06, 0.28), and when excluding 
non-randomized studies, d+6–8-month = 0.20 (95% CI = 0.09, 0.31) and d+12-month = 0.18 
(95% CI = 0.07, 0.31).
Subgroup Analyses: Between-study factors—This review had limited power to 
detect significant moderation, and heterogeneity analyses showed that there was little 
between-study variation to capture in moderator analyses. None of our hypothesized 
moderators accounted for a significant amount of heterogeneity in ESs. Therefore, we focus 
on analyses evaluating whether PRP’s effects were significant in subgroups of interest. 
Moderation statistics (between-group Q statistics) are available in Supplemental Table 6.
The mean ES for targeted studies was significant at all three assessments: d+post = 0.14 (95% 
CI = 0.01, 0.26); d+6–8-month = 0.23 (95% CI = 0.11, 0.36); d+12-month = 0.22 (95% CI = 
0.06, 0.38). The mean ES among universal studies was significant at the 12-month follow-
up, d+ = 0.19 (95% CI = 0.01, 0.37), but not at post-intervention, d+ = 0.06 (95% CI = 
−0.10, 0.23), or the 6- to 8-month follow-up, d+ = 0.15 (95% CI = -0.02, 0.33). The effects 
among both research team leaders and community providers were non-significant at post-
intervention: d+ = 0.20 (95% CI: −0.02, 0.41) and d+ = 0.08 (95% CI: −0.04, 0.19), 
respectively. The mean ESs for both research team and community leaders were significant 
at the 6–8-month assessment, however: d+ = 0.29 (95% CI: 0.06, 0.53) and d+ = 0.17 (95% 
CI: 0.06, 0.28), respectively. The mean ESs for both research team and community leaders 
remained significant at 12-month follow-up: d+ = 0.31 (95% CI: 0.03, 0.60) and d+ = 0.18 
(95% CI: 0.05, 0.32), respectively (see Supplemental Table 7).
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Subgroup Analyses: Within-study factors—PRP’s effect among girls was significant 
at 6–8-month follow-up, d+ = 0.19 (95% CI: 0.02, 0.35), but not at post-intervention, d+ = 
0.06 (95% CI: −0.11, 0.22) or 12-month follow-up, d+ = 0.16 (95% CI: −0.01, 0.32). PRP’s 
effects among boys were significant at both follow-up assessments, d+6–8-Month = 0.21 (95% 
CI: 0.05, 0.37) and d+12Month = 0.25 (95% CI: 0.08, 0.41), but were not significant at post-
intervention, d+ = 0.05 (95% CI: −0.12, 0.22). PRP’s effects among low symptom 
participants were significant at all assessments: d+post = 0.13 (95% CI = 0.02, 0.24); 
d+6–8-month = 0.15 (95% CI = 0.01, 0.29); d+12-month = 0.19 (95% CI = 0.04, 0.34). Effects 
among participants with elevated symptoms were significant at both follow-up assessments, 
d+6–8-month = 0.28 (95% CI = 0.03, 0.53) and d+12-month = 0.27 (95% CI = 0.04, 0.51), but 
not at post-intervention, d+post = 0.18 (95% CI = −0.03, 0.39) (see Supplemental Table 9).
Depressive Disorders
The mean IRR comparing PRP and no-intervention control conditions was 0.89 (95% CI: 
0.64, 1.24), indicating that PRP participants were approximately 11% less likely to receive a 
depression diagnosis. Individual study IRRs ranged from 0.80 to 1.10. The mean RR was 
0.90 (95% CI: 0.66, 1.23) indicating a risk reduction of 10% in the PRP group. Neither of 
these effects represents a significant benefit of PRP. Overall, 75 out of 622 PRP participants 
(totaling 1238 PYs) met criteria for a depressive disorder as compared to 68 out of 470 
control group participants (totaling 920 PYs). The NNT across all three studies was equal to 
41 (see Supplemental Table 11).
PRP did not significantly reduce the risk for depressive disorders among any subgroups 
examined. However, preliminary analyses suggest that boys and participants with elevated 
symptoms may benefit from PRP more than girls and low symptom participants. Among 
boys, the mean IRR was 0.74 (95% CI: 0.45, 1.24), representing a 26% reduction in 
incidence in the PRP group, compared to a mean IRR among girls of 1.02 (95% CI: 0.65, 
1.59). PRP participants with elevated symptoms were 16% less likely to have a diagnosis 
[IRR+= 0.84, (95% CI: 0.52, 1.36)] compared to no-intervention control participants with 
elevated symptoms, while there was practically no benefit for low symptom PRP 
participants [IRR+= 0.94, (95% CI: 0.58, 1.51)]. The NNT among boys and participants with 
elevated symptoms was 23 and 16, respectively, compared to 238 and 65 among girls and 
low symptom participants (see Supplemental Table 12).
Discussion
Effects on Depressive Symptoms
The primary goal of this meta-analysis was to determine whether PRP is effective in 
targeting depressive symptoms. We found that youth who participate in PRP report reliably 
lower levels of depressive symptoms through 12 months of follow-up compared to youth 
who receive no intervention. The effects are modest (ranging from 0.11 to 0.21) but of a 
similar magnitude to those reported in larger meta-analyses of depression prevention 
programs (Horowitz & Garber, 2006; Jané-Llopis et al, 2003; Merry et al., 2004; Stice et al., 
2009). (Direct comparisons with other depression prevention meta-analyses should be made 
cautiously given that there are important methodological differences between the studies.) 
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On average, PRP groups scored between 0.86 and 1.75 points lower on the CDI than no-
intervention control groups. A single point on the CDI is indicative of a change in the 
frequency or intensity of a depressive symptom.
It is unclear at this time why PRP’s effects became more robust at the follow-up assessments 
than at post-intervention. We considered the possibility that control participants had an 
increase in depressive symptoms in the first year following the study creating more room for 
an intervention effect. To evaluate this possibility, we calculated mean depressive symptom 
scores at each assessment across all studies using the CDI, weighting each study’s mean 
symptom score by its sample size. Contrary to expectation, the mean control group CDI 
score tended to decrease over the follow-up (from M = 9.39 at post to M = 8.80 at 12-month 
follow-up). In 7 of the 8 studies reporting 12-month data, the control group reported 
decreases in symptoms from post-intervention to 12-month follow-up. The strengthening of 
PRP’s effects cannot be attributed to an increase in control group symptoms. We also 
considered the possibility that studies with small post-intervention effects were less likely to 
collect follow-up data leading to overestimates of mean ESs at follow-up assessments. This 
seems unlikely given that two of the three studies (Tellier, 1998; Wass, 2008) with only 
post-intervention data available had larger than average effects (0.39 and 0.51, respectively). 
It is also possible that PRP’s effects truly grow stronger over time. It may take time before 
students begin applying the program skills in their everyday lives. Future research should 
examine the relationship between participants’ use of the PRP skills and their depressive 
symptoms over time.
The limited data available show no evidence that PRP is superior to active control 
conditions at either post-intervention or 6–8-month follow-up. The dearth of statistical 
power in these analyses limits our ability to draw firm conclusions. However, the mean ES 
was not even in the expected direction at either post-intervention or 6–8-month follow-up 
suggesting that PRP is not superior to active control conditions. Future research should 
continue to compare PRP to active control conditions in terms of mental health outcomes 
and in terms of cost and ease of delivery.
Secondary Analyses
We also conducted moderator and subgroup analyses evaluating whether participant and 
group leader characteristics influence PRP’s effects. There was no evidence that any 
subgroup variables accounted for a significant amount of heterogeneity. Our ability to detect 
moderation was limited due to the relatively small sample of studies (k = 17), many of which 
were underpowered. However, it is important to note that heterogeneity levels were low 
(particularly at the follow-up assessments). This could mean that the between-study 
differences have little impact on PRP’s effects. As PRP research accumulates, meta-analysts 
should continue to evaluate whether contextual factors moderate PRP’s effects.
Participant characteristics—PRP’s effects tended to be larger (though not significantly) 
at all three assessments when delivered to targeted samples than when delivered universally. 
This is not surprising given that there is typically more room for an effect in targeted studies. 
Consistent with two previous meta-analyses (Horowitz & Garber, 2006; Merry et al., 2004) 
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we found no evidence for PRP’s effectiveness in universal studies at the post-intervention or 
6–8-month follow-up assessments. We did find a significant effect of universal studies on 
depressive symptoms at the 12-month follow-up (d+ = 0.19), however. This finding is 
consistent with findings from a recent meta-analysis of depression prevention programs in 
which effects of universally delivered interventions were not significant at post-intervention 
but were significant (though smaller than effects of targeted studies) across the long-term 
follow-up (Stice et al., 2009). Several prevention researchers have suggested that further 
research investigating universal prevention may not be warranted (e.g., Spence & Shortt, 
2007; Stice et al., 2009). However, given their significant longer-term effects and their 
potential to reach large numbers of youth, we believe it is important to continue efforts to 
develop and evaluate universal depression prevention programs.
We found evidence for PRP’s effectiveness among both boys and girls. The mean ES among 
boys was significant at both follow-up assessments, while the mean ES for girls was only 
significant at 6–8-month follow-up. It is noteworthy that the range in ESs among boys and 
girls was considerable. In two studies, there were particularly large discrepancies in the 
effects among boys and girls. The ESs for boys in the Reivich (1996) study were relatively 
large (ranging 0.35 to 0.61) while the effects for girls were remarkably poor (ranging from 
−0.39 to 0.06). Conversely, a different study (Gillham, Hamilton, et al., 2006) yielded 
consistently positive effects for girls (ranging from 0.21, to 0.34) and poorer effects for boys 
(ranging from −0.33 to 0.16). These findings suggest that contextual factors (e.g., the 
intervention setting or group leader characteristics) may influence PRP’s effects on boys and 
girls differently. For example, it could be that having single-sex PRP groups is beneficial for 
girls but not so for boys. PRP group leaders have noted in supervision that girls seem more 
engaged in the intervention and feel more comfortable talking about sensitive issues when 
the group is predominantly or entirely female. Chaplin and colleagues found that girls in 
single-sex groups attended more PRP sessions and had lower hopelessness scores than girls 
in coed groups, although both all-girls and co-ed PRP led to similar improvements in 
depressive symptoms relative to a no-intervention control (Chaplin et al., 2006). A study 
evaluating the influence of group characteristics (such as the gender composition of groups) 
on PRP outcomes is underway.
Group leader characteristics—The mean ESs for studies with research team leaders 
tended to be larger (although not significantly) than those among studies with community 
leaders at all three assessments; however, the mean ESs were significant at both follow-ups 
regardless of whether intervention providers were primarily members of the research team 
or community leaders. As more studies of PRP are conducted, it will be important to revisit 
the question of whether there is a drop-off in intervention effects when real-world personnel 
lead intervention groups. It is encouraging that PRP’s effects were significant with 
community leaders as effective dissemination is contingent upon PRP’s success when led by 
real-world personnel.
Effects on Depressive Disorders
PRP did not have a significant effect on diagnoses of depression. Given that only three 
studies of PRP measured diagnostic outcomes we did not expect to have enough statistical 
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power to detect a significant intervention effect. PRP participants were only 11% less likely 
than controls to receive a diagnosis and 41 participants are needed to prevent one case of 
depression. Our preliminary analyses suggest there may be diagnostic benefits for boys and 
participants with elevated symptoms but there is no evidence of benefit for girls or low 
symptom participants.
Very few studies of depression prevention programs for youth have measured effects on 
depression diagnoses. A recent meta-analysis of depression prevention studies for 
adolescents and adults found that participants in prevention programs were 23% less likely 
than controls to be diagnosed with depression and that 21 participants needed to receive the 
intervention to prevent one case of depression (Cuijpers et al., 2008). PRP’s effects on 
diagnosis appear to be about half this size. There are several possible explanations for this 
discrepancy. It is possible that PRP’s effects on depressive symptoms do not translate into 
prevention of diagnoses. Alternatively, the discrepancies may reflect differences in 
participants’ ages. The vast majority of studies that have examined the prevention of 
disorder include participants in late adolescence through adulthood when depression rates 
are high. In contrast, PRP targets early adolescents, who are far less likely to have clinical 
depression and who may have more difficulty learning and applying cognitive-behavioral 
skills. A third possibility is that differences in effects reflect differences in risk status. On 
average, participants in the PRP studies that examined diagnoses scored 9.9 on the baseline 
CDI (which is between the 57th and 69th percentile depending on participant age and sex; 
Kovacs, 2001), while most other studies examining prevention of depressive disorders have 
selected participants at substantially elevated risk.
Questions & Recommendations for Future Research
This meta-analysis indicates that PRP participants have reliably lower levels of depressive 
symptoms compared to participants who receive no intervention, and these effects endure 
for at least 12-months after the intervention. However, this review leaves us with more 
questions than answers. PRP was developed with the intention of widespread 
implementation leading to a considerable decrease in the burden of depression. Clearly, this 
lofty goal is far from accomplished. Future research should address the following questions.
(1) Are PRP’s effects meaningful?—The most important objective for future PRP 
research will be to demonstrate that PRP’s effects have practical significance. We propose a 
broad definition for what constitutes a meaningful intervention effect as one that leads to 
improvements in the emotional health or functioning of the participants, their family 
members, and/or peers. There are many ways in which PRP could produce meaningful 
benefits including, but not limited to, the following: (a) preventing, delaying, or lessening 
the intensity or duration of future psychological disorders; (b) eliminating or ameliorating 
the distress and impairment associated with sub-clinical symptoms of depression, anxiety, or 
externalizing problems; (c) improving interpersonal relationships with peers and/or family 
members; (d) increasing awareness of youth depression among participants, teachers, and 
guardians, and improving their ability to respond effectively; and (e) improving parental 
well-being and parenting practices (which is the goal of the parent intervention component).
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At this time, it is unclear whether PRP yields these benefits. There is no evidence at this 
time that PRP satisfies our criterion (a) as effects on depressive disorders were not 
significant. PRP is closest to meeting criterion (b). PRP has enduring effects on depressive 
symptoms but it is unclear whether an average reduction in symptoms by one-fifth of a 
standard deviation translates into practical benefits for youth. PRP’s effects are small by 
many intervention researchers’ standards (e.g., Weisz, Donenberg, Han, & Weiss, 1995). 
But the meaningfulness of an effect is not simply a function of its magnitude (Prentice & 
Miller, 1992). Many widely-accepted interventions yield small effects, comparable to PRP’s 
effects on depressive symptoms (Meyer et al., 2001). The important question is whether 
PRP’s small effect on depressive symptoms is a mediator of practical benefits for youth 
(e.g., decreased risk for depressive disorders, improved adaptive functioning, quality of life, 
etc.). Future PRP studies should include outcome measures that better lend themselves to 
clinical interpretation.
In the short term, effects among youth with elevated depressive symptoms are likely more 
meaningful than effects among students who already have low levels of symptoms. This 
review suggests that PRP is effective in reducing symptoms among students with elevated 
baseline symptoms. But PRP is not intended to be a short-term treatment program; rather it 
is intended to impart lasting skills that will reduce the risk for depression as youth enter late 
adolescence and early adulthood. Unfortunately, few PRP studies have been able to follow 
youth into this period of heightened risk. Extending follow-up periods would be difficult due 
to increased costs and attrition, but doing so would improve our ability to gauge PRP’s 
potential benefits. It is noteworthy that, although screening instruments can be effective in 
identifying youth at increased risk for depression, many (and perhaps more) youth who 
score low on these instruments at a screening or baseline assessment will ultimately develop 
significant levels of depression (Gillham, 2003). Thus, we feel that, in the long-term, PRP’s 
effects among low symptom youth could be just as meaningful as its effects among 
participants with elevated symptoms.
It is likely that PRP’s effects extend beyond depression. The program is based on CBT skills 
that are used in the treatment of a variety of psychological disorders (Butler, Chapman, 
Forman, & Beck, 2006). Given their high levels of comorbidity with depression, the PRP 
program developers included content specifically targeting anxiety and externalizing 
symptoms. Few PRP studies have evaluated these outcomes, but there is some evidence that 
PRP can improve anxiety and externalizing symptoms (Gillham, Reivich, et al., 2006; 
Jaycox, Reivich, Gillham, & Seligman, 1994; Roberts, Kane, Bishop, Matthews, & 
Thomson, 2004). Research that evaluates PRP’s effects on anxiety, behavioral problems, 
and other outcomes can lead to better estimates of the program’s true impact.
(2) Is PRP cost-effective?—Demonstrating meaningful benefits is insufficient 
justification for PRP’s widespread dissemination; researchers must also demonstrate that the 
program is a good investment of resources. Findings from a recent study support the cost-
effectiveness of a CBT-based depression prevention program similar to PRP (Lynch et al., 
2005). This finding is encouraging and should prompt similar studies evaluating PRP’s cost-
effectiveness. Researchers should consider the cost-effectiveness of PRP in relation to 
attention-control conditions and alternative interventions.
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The cost of PRP’s delivery depends on many factors including the method of its delivery. 
There are benefits and drawbacks to both universal and targeted prevention approaches (see 
Offord, Kraemer, Kazdin, Jensen, & Harrington, 1998). Targeted interventions, for example, 
have high costs associated with identifying and recruiting at-risk participants. However, 
universal prevention requires a greater number of intervention group leaders, which 
increases compensation and training expenses. Future research should consider the cost-
effectiveness of universal and targeted prevention strategies separately. It is important to 
consider the potentially wide-range of benefits listed in the previous section when evaluating 
PRP’s cost-effectiveness. Small improvements in a variety of domains could translate into 
large overall benefits, subsequently improving cost-effectiveness estimates.
(3) How does PRP work?—Uncovering the causal mechanisms responsible for PRP’s 
effects on depressive symptoms should be priority for future research. Theoretically, PRP 
works by improving cognitive style and coping skills. A number of PRP studies have taken 
steps to test this causal model of change with mixed findings. At least four PRP studies have 
evaluated cognitive style as a mediator of PRP’s effects on depressive symptoms, and three 
found at least partial support for the model (Cardemil, et al., 2002; Gillham et al., 1995; 
Roberts, et al., 2004; Yu & Seligman, 2002). Several studies did not find significant 
intervention effects on depressive symptoms or cognitive style, precluding mediation 
analyses. Future meta-analyses should attempt to test whether the hypothesized mediation 
model holds across studies. Researchers seldom report the data needed to test mediation in 
meta-analysis, making this a difficult task.
The limited data available provide no evidence that PRP is superior to active control 
conditions that do not target cognitive risk factors. This is consistent with findings from a 
previous review of depression prevention studies (Merry, et al., 2004). The simplest 
explanation for this finding is that PRP’s effects on depressive symptoms are attributable to 
factors other than its CBT-based training, like increased attention, expectation of benefit, or 
group cohesion. It is important, however, to examine the possibility that PRP’s effects are 
attributable to CBT skills and that the active comparison conditions produced comparable 
effects via other mechanisms. Future studies should continue evaluating potential mediators 
of the effects of both PRP and active control conditions. Doing so will advance our 
understanding of why these programs produce benefits (when they indeed do produce 
benefits). PRP researchers should consider whether active control conditions are effective, 
and less costly, alternative interventions.
There is evidence from dismantling studies in the depression treatment literature that the 
behavioral, not cognitive, components of CBT may be primarily responsible for treatment 
gains (Jacobson, et al., 1996). PRP teaches a variety of behavioral coping and problem-
solving skills, but few studies have evaluated the cognitive and behavioral program 
components separately. Future studies should examine these behavioral skills as potential 
mediators of PRP’s effects. If behavioral components are the active ingredient, it may be 
prudent to revise the program putting greater emphasis on these skills.
(4) Is PRP effective when delivered under real-world conditions?—Intervention 
effects often decline when programs are transported from university research centers to real-
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world delivery settings (Weisz et al, 1995). Our finding that community leaders can deliver 
PRP effectively is an important step towards effective dissemination. However, this finding 
alone is not sufficient evidence of PRP’s ability to produce effects in community settings. In 
most studies evaluating community group leaders, the PRP intervention developers provided 
direct training and ongoing supervision to the group leaders. Such training and supervision 
may not be feasible if the program is widely disseminated. There were too few studies to 
evaluate PRP’s effectiveness when delivered by community leaders who did not receive 
direct training and supervision from the program developers. More research is needed to 
determine the type of training required for leaders to deliver PRP effectively. We encourage 
PRP researchers to carefully document their group leader training procedures so that future 
meta-analyses can evaluate whether training methods influence intervention outcomes. 
Additionally, more research is needed to determine if PRP is effective when implemented 
under real-world conditions (i.e., in schools and other community settings).
Limitations
This review had several notable limitations. First, we lacked statistical power to evaluate 
moderators and diagnostic outcomes reliably. Second, we had insufficient data to examine 
PRP’s theoretical model of change (i.e., that improvements in cognitive style and coping 
skills mediate intervention effects on depression-related outcomes). Third, we had 
insufficient data to evaluate important outcomes of interest, like adaptive functioning. 
Finally, we used an ES statistic (d) that assumes normality in the distributions of the two 
groups under comparison (Acion, et al., 2006). This ES statistic is commonly used in 
intervention research, including recent meta-analyses of depression prevention programs 
(e.g., Horowitz & Garber, 2006). Scores on depression measures are rarely normally 
distributed in non-clinical samples, however; distributions tend to be positively skewed 
because many participants have few or no symptoms. This may have led to biases in our 
mean ES estimates. Although there are ES statistics that make less restrictive assumptions, 
like PS, the information necessary for their calculation (e.g., a U statistic) is rarely reported 
in intervention studies.
Conclusion
This review confirms that adolescents who participate in the Penn Resiliency Program have 
fewer depressive symptoms than participants in no-intervention control conditions as late as 
12-months post-intervention. While it is encouraging that PRP has enduring effects on 
symptoms, average effects are small. The top priority of future PRP research should be to 
determine whether PRP has a meaningful impact on the lives of its participants. Research 
should examine whether PRP improves adaptive functioning and quality of life, and reduces 
risk for major mental health problems. PRP aims to provide youth with skills that will help 
them navigate through adolescence, a time of greatly increased risk, without succumbing to 
depression and its sequelae. Yet most PRP research has not followed participants past early 
adolescence. Future research should evaluate PRP’s effects throughout the adolescent years. 
Other priorities include identifying mediators and moderators of PRP’s effects and 
demonstrating that the program is transportable and cost-effective.
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Figure 1. 
Flow of studies included and excluded from the meta-analytic review.
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